Oncology & Cancer

Team develops and validates three-in-one CAR T therapy

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted ...

Oncology & Cancer

Engineering the immune system to tackle glioblastoma

Each year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primary brain tumor in adults, and also the most lethal. Surgery, radiation, and chemotherapy can help slow the ...

Medical research

S1P and its receptor: New approaches to cancer?

In 1998, when Timothy Hla, Ph.D., and his colleagues identified and cloned the receptor for sphingosine-1-phosphate (S1P), it generated a lot of excitement. S1P, a lipid originally discovered in the 1960s, was known to play ...

Immunology

Immune responses in chronic inflammatory bowel diseases

Chronic inflammatory bowel diseases (IBDs) like Crohn's disease and ulcerative colitis are characterized by inflammation of the gastrointestinal tract which flares up in phases and which is accompanied by abdominal pain, ...

Oncology & Cancer

Combining CAR-T cells and inhibitor drugs for high-risk neuroblastoma

Chimeric antigen receptor (CAR)-T cell therapy is a potent emerging weapon against cancer, altering patients' T cells so they can better find and destroy tumor cells. But CAR-T cell therapy doesn't work well in every cancer—including ...

page 12 from 26